Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol

Peter P. Toth,Sarah Bray,Guillermo Villa,Tamara Palagashvili,Naveed Sattar,Erik S. G. Stroes,Gavin M. Worth

DOI: https://doi.org/10.1161/JAHA.122.025551

2022-09-09

Abstract:Background Lowering low‐density lipoprotein cholesterol (LDL‐C) levels decreases major cardiovascular events and is recommended for patients at elevated cardiovascular risk. However, appropriate doses of statin therapy are often insufficient to reduce LDL‐C in accordance with current guidelines. In such cases, treatment could be supplemented with nonstatin lipid‐lowering therapy. Methods and Results A systematic literature review and network meta‐analysis were conducted on randomized controlled trials of nonstatin lipid‐lowering therapy added to maximally tolerated statins, including statin‐intolerant patients. The primary objective was to assess relative efficacy of nonstatin lipid‐lowering therapy in reducing LDL‐C levels at week 12. Secondary objectives included the following: LDL‐C level reduction at week 24 and change in non–high‐density lipoprotein cholesterol and apolipoprotein B at week 12. There were 48 randomized controlled trials included in the primary network meta‐analysis. All nonstatin agents significantly reduced LDL‐C from baseline versus placebo, regardless of background therapy. At week 12, evolocumab, 140 mg every 2 weeks (Q2W)/420 mg once a month, and alirocumab, 150 mg Q2W, were the most efficacious regimens, followed by alirocumab, 75 mg Q2W, alirocumab, 300 mg once a month, inclisiran, bempedoic acid/ezetimibe fixed‐dose combination, and ezetimibe and bempedoic acid used as monotherapies. Primary end point results were generally consistent at week 24, and for other lipid end points at week 12. Conclusions Evolocumab, 140 mg Q2W/420 mg once a month, and alirocumab, 150 mg Q2W, were consistently the most efficacious nonstatin regimens when added to maximally tolerated statins to lower LDL‐C, non–high‐density lipoprotein cholesterol, and apolipoprotein B levels and facilitate attainment of guideline‐recommended risk‐stratified lipoprotein levels. Nonstandard Abbreviations and Acronyms ESC European Society of Cardiology FDC fixed‐dose combination LLT lipid‐lowering therapy mAb monoclonal antibody MACE major adverse cardiovascular event NMA network meta‐analysis PCSK9 proprotein convertase subtilisin/kexin type 9 Q2W every 2 weeks Q3M every 3 months Q6M every 6 months QD once a day QM once a month SLR systematic literature review Clinical Perspective What Is New? There are few network meta‐analyses comparing the efficacy of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors; this study compared PCSK9 inhibitors and new lipid‐lowering therapies (LLTs) (ie, bempedoic acid and inclisiran). Primary network meta‐analysis found all nonstatin LLTs significantly reduced low‐density lipoprotein cholesterol levels versus placebo at week 12; broadly similar results for ranking of the interventions were identified in other lipid end point level changes. Evolocumab, 140 mg every 2 weeks/420 mg once a month, and alirocumab, 150 mg every 2 weeks, treatment resulted in >70% of a simulated population achieving the very high‐risk cardiovascular disease European guideline goal (<55 mg/dL). What Are the Clinical Implications? Evolocumab and alirocumab, 150 mg every 2 weeks, are the most consistently efficacious nonstatin LLT regimens. The network meta‐analysis of multiple nonstatin LLTs should help inform physicians' treatment choice for patients who would benefit from lower low‐density lipoprotein cholesterol levels and require adjuvant LLTs to statin therapy to achieve current low‐density lipoprotein cholesterol goals. Low‐density lipoprot -Abstract Truncated-